SRI International

SRI International awarded $100M radiation contract

Friday, October 23, 2015

SRI International has been awarded a resource contract of up to $100 million over five years by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, for the development of products to mitigate or treat acute or delayed effects of radiation exposure. Under the multiyear contract, SRI Biosciences, a division of SRI International, will provide services, facilities, expertise and capabilities to advance the development of radiation/nuclear medical countermeasure therapies from early-stage discovery toward licensure or approval by the FDA.

[Read More]

SRI International opens clinical trial unit in Michigan

Monday, October 27, 2014

SRI Biosciences, a division of SRI International, a California-based independent nonprofit research institute, has completed construction of an early-phase clinical trial facility in Plymouth, Mich. The 9,400-square-foot unit, located in the Michigan Life Science Innovation Center, now is open and fully equipped for early-stage human research studies of new medicines and medical devices. 

[Read More]

SRI International, Nobelpharma partner on endometriosis treatment

Thursday, September 11, 2014

SRI International, a California-based independent nonprofit research institute, and Nobelpharma, a Japanese pharmaceutical company, have entered into a licensing agreement to test SR16234, an SRI drug candidate that may be effective in treating endometriosis. SR16234 is a member of a class of drugs known as selective estrogen receptor modulators (SERMs) that regulate the effects of the hormone estrogen.

[Read More]

NIAID awards SRI International $49M to study new therapies for HIV and AIDS

Monday, July 28, 2014

SRI International has been awarded a new $49 million, seven-year contract with the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, to conduct preclinical development of potential therapies for HIV infection and AIDS. The contract supports the development of drugs to treat HIV and AIDS and the complications and opportunistic infections associated with the disease, as well as microbicides for preventing sexual transmission of HIV.

[Read More]

Rathnam Chaguturu joins SRI International

Monday, January 30, 2012

Rathnam Chaguturu, Ph.D., has joined SRI International‘s Center for Advanced Drug Research (CADRE) as senior director of exploratory research. Chaguturu will partner with SRI’s drug discovery and development teams and expand collaborative research relationships with academia, disease foundations, nonprofits and government agencies.

[Read More]

Fang joins SRI as director of clinical manufacturing

Thursday, December 8, 2011

Jia-Hwa Fang, Ph.D., has joined SRI’s biosciences division as director of clinical manufacturing. In this new role, he will lead a team to transfer and scale-up R&D, Good Laboratory Practice (GLP), and pilot formulations for early stage clinical
trial materials in compliance with Good Manufacturing Practices (GMP). He will be responsible for developing technical, quality, and project specifications for studies in SRI’s pharmaceutical clinical manufacturing facility.

[Read More]